Ultragenyx Pharmaceutical Inc (RARE)
41.90
-0.71
(-1.67%)
USD |
NASDAQ |
May 17, 16:00
41.90
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Debt to Equity Ratio: 0.00 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
Date | Value |
---|---|
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
December 31, 2017 | 0.00 |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.00 |
March 31, 2017 | 0.00 |
December 31, 2016 | 0.00 |
September 30, 2016 | 0.00 |
June 30, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
--
Maximum
Jun 2019
--
Average
--
Median
Jun 2019
Debt to Equity Ratio Benchmarks
Insulet Corp | 1.772 |
Sarepta Therapeutics Inc | 1.289 |
FibroGen Inc | -0.3166 |
Apellis Pharmaceuticals Inc | 0.3491 |
Amylyx Pharmaceuticals Inc | 0.00 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 1.307B |
Total Liabilities (Quarterly) | 1.167B |
Shareholders Equity (Quarterly) | 140.26M |
Current Ratio | 2.427 |